Mammaglobin B may be a prognostic biomarker of uterine corpus endometrial cancer.

Mammaglobin B, also referred to as secretoglobin family 2A member 1 (), has been reported to be highly expressed in uterine corpus endometrial cancer (UCEC) compared with in the normal endometrium. However, the prognostic value of in UCEC remains unclear. The Oncomine, The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium databases were used to explore the differential expression of . Furthermore, data of patients with UCEC were downloaded from TCGA, and logistic regression analysis, survival analysis, univariate and multivariate analyses, and nomogram construction were performed to identify its prognostic value in UCEC. Additionally, gene set enrichment analysis (GSEA) was utilized to estimate the mechanisms of in UCEC. Finally, immune infiltration of in UCEC was analyzed using the Tumor Immune Estimation Resource. Decreased mRNA and protein expression levels of were significantly associated with poor prognostic clinicopathological characteristics (all P<0.05). Additionally, low expression levels of were associated with decreased survival of patients with UCEC compared with high expression levels of . Furthermore, the independent prognostic value of in UCEC was identified by univariate and multivariate analyses. A nomogram based on 6 variables, including expression, was developed for the estimation of the 1-, 3-, and 5-year survival probability in UCEC. Additionally, GSEA suggested that the vascular endothelial growth factor, PTEN, platelet-derived growth factor, DNA repair, KRAS signaling, and PI3K-AKT-mTOR signaling pathways were differentially enriched in the low expression phenotype. Finally, high infiltration levels of CD8 T cells were associated with in UCEC and this was associated with prognosis. The present results indicated that may be a promising independent prognostic factor in UCEC. These signaling pathways may be crucial for the regulation of UCEC via .